THC: CBD spray and MS spasticity symptoms: Data from latest studies

European Neurology

Volumn 71, Issue SUPPL. 1, 2014, Pages 4-9

  Rekand, Tiina ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cannabinoids; CBD; Cognition; Driving; Multiple sclerosis; Registry; Spasticity; THC

Indexed keywords

BACLOFEN; NABIXIMOLS; PLACEBO; TOLPERISONE; BENZODIAZEPINE DERIVATIVE; TIZANIDINE;

ADULT; AEROSOL; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE REGISTRY; DIZZINESS; DRIVING ABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERMANY; HUMAN; MALE; MIDDLE AGED; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SPAIN; SPASTICITY; SPRAIN; SYMPTOM; THROMBOSIS; TREATMENT DURATION; UNITED KINGDOM; VERTIGO; COGNITION; DISEASE SEVERITY; FATIGUE; LONG TERM CARE; PHASE 3 CLINICAL TRIAL (TOPIC); SUICIDAL IDEATION;

AFFECT; AUTOMOBILE DRIVING; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; ORAL SPRAYS; PARASYMPATHOLYTICS; PLANT EXTRACTS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893503263     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000357742     Document Type: Article

References (10)

1. Novotna A, Mares J, Ratcliffe S, et al: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols . (Sativex ( ® ) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131.
2. Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabisbased medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296.
3. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459.
4. Wade D, Makela P, Robson P, House H, Bateman C: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-441.
5. Wade DT, Makela PM, House H, Bateman C, Robson P: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-645.
6. Garcia-Merino A: Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013; 13: 9-13.
7. Robson P: Abuse potential and psychoactive effects of d-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-685.
8. Friedel M, Tiel-Wilck K, Schreiber H, Lang M: Treatment of resistant MS spasticity with THC:CBD spray and effects on driving ability. Presented at ECTRIMS 2013.
9. Wright S, Vachova MM, Novakova I: The effect of long-term treatment with a prescription cannabis-based THC:CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to Multiple Sclerosis. Presented at ECTRIMS 2013.
10. Eltayb A, Etges T, Wright S: An observational post approval registry study of patients prescribed Sativex ® . Results from clinical practice. Presented at ECTRIMS 2013.